Results 271 to 280 of about 13,963,189 (308)
Some of the next articles are maybe not open access.
Primary biliary cholangitis: Personalizing second-line therapies
HepatologyPrimary biliary cholangitis (PBC) is an enigmatic, autoimmune disease targeting the small intralobular bile ducts resulting in cholestasis and potentially progression to biliary cirrhosis. Primarily affecting middle-aged women, the diagnosis of PBC is typically straightforward, with most patients presenting with cholestatic liver tests and the highly ...
Cynthia Levy, Christopher L. Bowlus
openaire +2 more sources
[Second-line therapy for Helicobacter pylori].
Nihon rinsho. Japanese journal of clinical medicine, 2013Currently, the recommended second-line eradication regimen for Helicobacter pylori is a quadruple therapy consisting of PPI, bismuth, tetracycline and metronidazole. Recently, levofloxacin-based (PPI, levofloxacin and amoxicillin) and moxifloxacin-based (PPI, moxifloxacin and amoxicillin) triple therapy represent promising alternative.
Daisuke, Asaoka +4 more
openaire +1 more source
Second-line antiretroviral therapy and the human factor
The Lancet HIV, 2015Ignacio, Pérez-Valero, José R, Arribas
openaire +2 more sources
Second-line therapy in colorectal cancer.
Oncology (Williston Park, N.Y.), 2001Second-line therapy is a relatively new concept for gastrointestinal oncologists. Although retreatment with fluorouracil (5-FU) is common, offering colorectal cancer patients a different chemotherapeutic agent as second-line therapy is a fairly recent strategy.
openaire +1 more source
Dolutegravir for second-line antiretroviral therapy
The Lancet Infectious Diseases, 2019openaire +3 more sources